Levodopa is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. It is available as inhalation capsules. MedsAcross supplies Levodopa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa
Source: US FDA prescribing information
Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
Source: US FDA prescribing information
INBRIJA capsules are for oral inhalation only and should be used only with the INBRIJA inhaler. For oral inhalation only. DO NOT swallow INBRIJA capsules. Only use INBRIJA capsules with the INBRIJA inhaler. Inhale the contents of two INBRIJA capsules (84 mg) as needed for OFF symptoms, up to 5 times daily. The maximum dose per OFF period is 84 mg, and the maximum recommended daily dosage of INBRIJA is 420 mg
Source: US FDA prescribing information
INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. Hypertension can occur if these drugs are used concurrently. INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor or who have recently (within 2 weeks) taken a nonselective MAO inhibitor
Source: US FDA prescribing information
May cause falling asleep during activities of daily living. Avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal-emergent hyperpyrexia and confusion. Hallucinations/exacerbation of psychosis may occur. Patients with a major psychotic disorder should not be treated with INBRIJA. Impulse Control Disorders: consider dose reduction or stopping INBRIJA. May cause or exacerbate dyskinesia: adjustment of levodopa therapy may be considered, including stopping INBRIJA. Not recommended in patients with asthma, COPD, or other chronic underlying lung disease
Source: US FDA prescribing information
The following serious adverse reactions are discussed below and elsewhere in the labeling: Falling Asleep During Activities of Daily Living and Somnolence Withdrawal-Emergent Hyperpyrexia and Confusion Hallucinations/Psychosis Impulse Control/Compulsive Behaviors Dyskinesia Bronchospasm in Patients with Lung Disease Glaucoma The most common adverse reactions (incidence ≥ 5% and higher than placebo) were cough, nausea, upper respiratory tract infection, and sputum discolored
Source: US FDA prescribing information
Monitor patients on MAO-B inhibitors for orthostatic hypotension. Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA
Source: US FDA prescribing information
Store in a dry place between 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). INBRIJA capsules should always be stored in the blister packaging and only removed immediately before use. INBRIJA capsules should not be stored inside the INBRIJA inhaler.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Levodopa, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Inbrija 42 mg inhalation capsuleInhalation | Merz Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Levodopa in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Levodopa and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Levodopa, including Inbrija.
Yes. The US FDA first approved Levodopa on 4 June 1970, according to Drugs@FDA.
Yes. Levodopa has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Levodopa is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Levodopa is classified under ATC code N04BA01 (Levodopa).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.